<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005510</url>
  </required_header>
  <id_info>
    <org_study_id>44731</org_study_id>
    <secondary_id>R01CA168598</secondary_id>
    <nct_id>NCT02005510</nct_id>
  </id_info>
  <brief_title>Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women</brief_title>
  <official_title>Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether mailing in-home human papillomavirus (HPV)&#xD;
      screening kits is effective in increasing uptake of cervical cancer screening and early&#xD;
      detection and treatment of cervical neoplasia in underscreened women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over half of all cervical cancers in the U.S. are diagnosed in unscreened or underscreened&#xD;
      women. New national guidelines identify increasing screening uptake as the number one&#xD;
      priority for reducing cervical cancer-related morbidity and mortality. Innovative screening&#xD;
      strategies that eliminate the need for clinic-based screening could be highly effective in&#xD;
      improving screening compliance while maintaining high-quality care. We propose a large,&#xD;
      pragmatic randomized controlled trial within Group Health (a large integrated health care&#xD;
      delivery system in Washington State) to compare effectiveness of two programmatic approaches&#xD;
      to increasing cervical cancer screening among overdue women. The first approach (control arm)&#xD;
      is usual care at Group Health, which consists of patient- and provider-level services to&#xD;
      promote adherence to Pap screening, and the second approach (intervention arm) includes usual&#xD;
      care plus a mailed in-home high-risk human papillomavirus (hrHPV) screening kit. We will&#xD;
      randomize eligible women to the in-home hrHPV screening arm or the usual care arm. Compared&#xD;
      to usual care, we hypothesize that in-home hrHPV screening will enhance early detection and&#xD;
      treatment of cervical neoplasia and improve compliance with screening. The trial will provide&#xD;
      definitive evidence-based data on the impact of an in-home hrHPV screening program in a&#xD;
      real-world clinical setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligibility is assessed weekly over 2.5 years. Study participants are assigned to the control arm or to the intervention arm. After follow-up is complete, control arm participants are re-assessed for eligibility and re-randomization.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Diagnosed With Cervical Epithelial Neoplasia Grade 2 or Worse</measure>
    <time_frame>Assessed for up to 12 months post-randomization</time_frame>
    <description>Histologic diagnosis of cervical intraepithelial neoplasia grade 2 or worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants That Received Treatment for Cervical Intraepithelial Neoplasia Grade 2 or Worse</measure>
    <time_frame>Assessed for up to 18 months post-randomization</time_frame>
    <description>Receipt of treatment for cervical intraepithelial neoplasia grade 2 or worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Completed Uptake of Cervical Cancer Screening</measure>
    <time_frame>Assessed for up to 6 months post-randomization</time_frame>
    <description>Uptake of cervical cancer screening is defined as either: [1] receipt of a Pap or co-test; [2] self-sample hrHPV-positive (16/18-negative) OR unsatisfactory AND receipt of follow-up diagnostic testing (Pap or co-test or colposcopy); [3] self-sample HPV16/18-positive; or [4] self-sample hrHPV-negative)&#xD;
Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for cervical cancer screening uptake for the in-home HPV screening arm versus the usual care arm.&#xD;
We will also use log-binomial regression to estimate the effects of EMR-derived patient characteristics (e.g. age, race/ethnicity, geocoded socioeconomic status, geocoded distance form primary care clinic, insurance type, time since last Pap test, tobacco use, obesity, and Charlson comorbidity score) on cervical cancer screening uptake, stratified subdivided by randomization arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Abnormal Screening Result</measure>
    <time_frame>Assessed for up to 6 months post-randomization</time_frame>
    <description>Screening result that warrants repeat testing, surveillance, or immediate colposcopy (per current guidelines) before returning to a routine screening schedule&#xD;
Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for an abnormal screening result for the in-home HPV screening arm versus the usual care arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experiences and Attitudes Associated With In-home HPV Testing Uptake</measure>
    <time_frame>Survey invitation mailed 6 months post-randomization</time_frame>
    <description>Experiences and attitudes will be measured with online surveys. A subset of intervention arm participants who do and do not return the in-home HPV kit will be invited to complete a survey (target n=200). We will examine psychosocial factors (e.g., cervical cancer/HPV knowledge, attitudes toward screening), experiences, and reactions to kits. We will compare responses in women who do versus do not return a mailed HPV kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experiences and Attitudes Associated With Follow-up of Positive In-home HPV Testing Results</measure>
    <time_frame>Interview invitation mailed after all recommended clinical follow-up complete OR study follow-up window complete, up to 12 months post-randomization</time_frame>
    <description>Intervention arm participants who return in-home HPV kits and test positive for HPV will be invited to complete an in-depth semi-structured interview (target n=50). We will explore patient perspectives following a positive human papillomavirus (HPV) self-sampling result to describe experiences and information needs for this home-based screening modality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19851</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>In-home HPV Screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mailed in-home high-risk HPV testing kit</intervention_name>
    <arm_group_label>In-home HPV Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <arm_group_label>In-home HPV Screening</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  30 to 64 years of age&#xD;
&#xD;
          -  Have a primary care provider at Group Health&#xD;
&#xD;
          -  Received annual &quot;birthday letter&quot; with Pap screening reminder 5 months earlier&#xD;
&#xD;
          -  No Pap test in the past 3.4 years&#xD;
&#xD;
          -  Continuously enrolled at Group Health for at least 3.4 years&#xD;
&#xD;
          -  No hysterectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Language interpreter needed&#xD;
&#xD;
          -  On &quot;do not contact list&quot; for research studies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel L Winer, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Washington Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>January 20, 2020</results_first_submitted>
  <results_first_submitted_qc>August 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Rachel Winer</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>screening</keyword>
  <keyword>human papillomavirus</keyword>
  <keyword>cervical intraepithelial neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02005510/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>In-home HPV Screening</title>
          <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized (Round 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8120">Excludes 163 determined to be ineligible post-randomization due to delays in data warehouse update.</participants>
                <participants group_id="P2" count="8111">Excludes 196 determined to be ineligible post-randomization due to delays in data warehouse update.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8120"/>
                <participants group_id="P2" count="8111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Rerandomized (Round 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1631">Excludes 10 determined to be ineligible post-randomization due to delays in data warehouse update.</participants>
                <participants group_id="P2" count="1585">Excludes 5 determined to be ineligible post-randomization due to delays in data warehouse update.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1631"/>
                <participants group_id="P2" count="1585"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Rerandomized (Round 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209">Excludes 5 determined to be ineligible post-randomization due to delays in data warehouse update.</participants>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are not available for 117 participants in the intervention arm who opted out of electronic medical record review.</population>
      <group_list>
        <group group_id="B1">
          <title>In-home HPV Screening</title>
          <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9843"/>
            <count group_id="B2" value="9891"/>
            <count group_id="B3" value="19734"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9843"/>
                    <measurement group_id="B2" value="9891"/>
                    <measurement group_id="B3" value="19734"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9843"/>
                    <measurement group_id="B2" value="9891"/>
                    <measurement group_id="B3" value="19734"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="486"/>
                    <measurement group_id="B2" value="8761"/>
                    <measurement group_id="B3" value="9247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8710"/>
                    <measurement group_id="B2" value="480"/>
                    <measurement group_id="B3" value="9190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="647"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="893"/>
                    <measurement group_id="B2" value="880"/>
                    <measurement group_id="B3" value="1773"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="438"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="869"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7018"/>
                    <measurement group_id="B2" value="7111"/>
                    <measurement group_id="B3" value="14129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="568"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="911"/>
                    <measurement group_id="B2" value="902"/>
                    <measurement group_id="B3" value="1813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9843"/>
                    <measurement group_id="B2" value="9891"/>
                    <measurement group_id="B3" value="19734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Diagnosed With Cervical Epithelial Neoplasia Grade 2 or Worse</title>
        <description>Histologic diagnosis of cervical intraepithelial neoplasia grade 2 or worse</description>
        <time_frame>Assessed for up to 12 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>In-home HPV Screening</title>
            <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Cervical Epithelial Neoplasia Grade 2 or Worse</title>
          <description>Histologic diagnosis of cervical intraepithelial neoplasia grade 2 or worse</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9960"/>
                <count group_id="O2" value="9891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Received Treatment for Cervical Intraepithelial Neoplasia Grade 2 or Worse</title>
        <description>Receipt of treatment for cervical intraepithelial neoplasia grade 2 or worse</description>
        <time_frame>Assessed for up to 18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>In-home HPV Screening</title>
            <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Received Treatment for Cervical Intraepithelial Neoplasia Grade 2 or Worse</title>
          <description>Receipt of treatment for cervical intraepithelial neoplasia grade 2 or worse</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9960"/>
                <count group_id="O2" value="9891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Completed Uptake of Cervical Cancer Screening</title>
        <description>Uptake of cervical cancer screening is defined as either: [1] receipt of a Pap or co-test; [2] self-sample hrHPV-positive (16/18-negative) OR unsatisfactory AND receipt of follow-up diagnostic testing (Pap or co-test or colposcopy); [3] self-sample HPV16/18-positive; or [4] self-sample hrHPV-negative)&#xD;
Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for cervical cancer screening uptake for the in-home HPV screening arm versus the usual care arm.&#xD;
We will also use log-binomial regression to estimate the effects of EMR-derived patient characteristics (e.g. age, race/ethnicity, geocoded socioeconomic status, geocoded distance form primary care clinic, insurance type, time since last Pap test, tobacco use, obesity, and Charlson comorbidity score) on cervical cancer screening uptake, stratified subdivided by randomization arm.</description>
        <time_frame>Assessed for up to 6 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>In-home HPV Screening</title>
            <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Completed Uptake of Cervical Cancer Screening</title>
          <description>Uptake of cervical cancer screening is defined as either: [1] receipt of a Pap or co-test; [2] self-sample hrHPV-positive (16/18-negative) OR unsatisfactory AND receipt of follow-up diagnostic testing (Pap or co-test or colposcopy); [3] self-sample HPV16/18-positive; or [4] self-sample hrHPV-negative)&#xD;
Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for cervical cancer screening uptake for the in-home HPV screening arm versus the usual care arm.&#xD;
We will also use log-binomial regression to estimate the effects of EMR-derived patient characteristics (e.g. age, race/ethnicity, geocoded socioeconomic status, geocoded distance form primary care clinic, insurance type, time since last Pap test, tobacco use, obesity, and Charlson comorbidity score) on cervical cancer screening uptake, stratified subdivided by randomization arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9960"/>
                <count group_id="O2" value="9891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2618"/>
                    <measurement group_id="O2" value="1719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Abnormal Screening Result</title>
        <description>Screening result that warrants repeat testing, surveillance, or immediate colposcopy (per current guidelines) before returning to a routine screening schedule&#xD;
Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for an abnormal screening result for the in-home HPV screening arm versus the usual care arm.</description>
        <time_frame>Assessed for up to 6 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>In-home HPV Screening</title>
            <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Abnormal Screening Result</title>
          <description>Screening result that warrants repeat testing, surveillance, or immediate colposcopy (per current guidelines) before returning to a routine screening schedule&#xD;
Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for an abnormal screening result for the in-home HPV screening arm versus the usual care arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9960"/>
                <count group_id="O2" value="9891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Experiences and Attitudes Associated With In-home HPV Testing Uptake</title>
        <description>Experiences and attitudes will be measured with online surveys. A subset of intervention arm participants who do and do not return the in-home HPV kit will be invited to complete a survey (target n=200). We will examine psychosocial factors (e.g., cervical cancer/HPV knowledge, attitudes toward screening), experiences, and reactions to kits. We will compare responses in women who do versus do not return a mailed HPV kit.</description>
        <time_frame>Survey invitation mailed 6 months post-randomization</time_frame>
        <population>A subset of intervention arm participants who do and do not return the in-home HPV kit will be invited to complete a survey.</population>
        <group_list>
          <group group_id="O1">
            <title>In-home HPV Screening</title>
            <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
          </group>
        </group_list>
        <measure>
          <title>Experiences and Attitudes Associated With In-home HPV Testing Uptake</title>
          <description>Experiences and attitudes will be measured with online surveys. A subset of intervention arm participants who do and do not return the in-home HPV kit will be invited to complete a survey (target n=200). We will examine psychosocial factors (e.g., cervical cancer/HPV knowledge, attitudes toward screening), experiences, and reactions to kits. We will compare responses in women who do versus do not return a mailed HPV kit.</description>
          <population>A subset of intervention arm participants who do and do not return the in-home HPV kit will be invited to complete a survey.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1355"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Kit returner and responded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kit returner and did not respond</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kit non-returner and responded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kit non-returner and did not respond</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Experiences and Attitudes Associated With Follow-up of Positive In-home HPV Testing Results</title>
        <description>Intervention arm participants who return in-home HPV kits and test positive for HPV will be invited to complete an in-depth semi-structured interview (target n=50). We will explore patient perspectives following a positive human papillomavirus (HPV) self-sampling result to describe experiences and information needs for this home-based screening modality.</description>
        <time_frame>Interview invitation mailed after all recommended clinical follow-up complete OR study follow-up window complete, up to 12 months post-randomization</time_frame>
        <population>Intervention arm participants who return in-home HPV kits and test positive for HPV will be invited to complete an in-depth semi-structured interview.</population>
        <group_list>
          <group group_id="O1">
            <title>In-home HPV Screening</title>
            <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
          </group>
        </group_list>
        <measure>
          <title>Experiences and Attitudes Associated With Follow-up of Positive In-home HPV Testing Results</title>
          <description>Intervention arm participants who return in-home HPV kits and test positive for HPV will be invited to complete an in-depth semi-structured interview (target n=50). We will explore patient perspectives following a positive human papillomavirus (HPV) self-sampling result to describe experiences and information needs for this home-based screening modality.</description>
          <population>Intervention arm participants who return in-home HPV kits and test positive for HPV will be invited to complete an in-depth semi-structured interview.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Kit HPV positive and interviewed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Kit HPV positive and not-interviewed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>In-home HPV Screening</title>
          <description>Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Mailed in-home high-risk HPV testing kit&#xD;
Usual care</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual care. &quot;Usual care&quot; consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.&#xD;
Usual care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9960"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9891"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9960"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9891"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9960"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9891"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Light bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9960"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9891"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9960"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9891"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rachel Winer</name_or_title>
      <organization>University of Washington</organization>
      <phone>2066165081</phone>
      <email>rlw@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

